On April 12, 2021 Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine,reported that promising new preclinical data of PTX-35 is presented at the AACR (Free AACR Whitepaper) Annual Meeting 2021 (Press release, Heat Biologics, APR 12, 2021, View Source [SID1234577891]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PTX5 is the company’s first antibody-based product, currently in a Phase 1 clinical trial for the treatment of patients with solid tumors. PTX-35 is a novel, potential first-in-class antibody modulating TNFRSF25 (death receptor 3), a receptor that is preferentially expressed by antigen-experienced T-cells. In a B16F10 melanoma mouse model, PTX-35 in the presence of tumor antigen supplied by Heat’s HS-110 immunotherapy, resulted in decreased regulatory T-cell suppression and enhanced T effector responses. These changes were associated with delayed tumor progression.

Jeff Wolf, Chief Executive Officer of Heat, commented, "PTX-35 is designed to harness the body’s natural antigen-specific immune activation. We believe our latest data suggest that PTX-35 can help overcome certain mechanisms of cancer immune evasion. We continue to advance our first-in-human Phase 1 study of PTX-35 in patients with solid tumors and look forward to sharing interim data later this year."

Details of the poster presentation are as follows:

Title: PTX-35, a Potential First-in-class Agonist, Reduced the Suppressive Activity of Regulatory T cells and Enhanced CD4+ T cell Effector Responses in the Presence of Tumor Antigens in a Murine Melanoma Model

Abstract Number: 604

Session: Modifiers of the Tumor Microenvironment

Presenter: Eric Dixon, Director of Discovery Sciences, Heat Biologics

About the AACR (Free AACR Whitepaper) Annual Meeting

The 2021 AACR (Free AACR Whitepaper) Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from population science and prevention to cancer biology, translational, and clinical studies, as well as survivorship and advocacy—and highlights the work of the best minds in research and medicine from institutions all over the world.

On April 12, 2021 Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported that Paul Levesque, President and Chief Executive Officer, will present at the Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 21, 2021 at 10:30 a.m. ET (Press release, Theratechnologies, APR 12, 2021, View Source [SID1234577908]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live webcast will be available at View Source The live and archived webcast link will also be available in the ‘News’ section of the Company’s website.

On April 12, 2021 Seneca Therapeutics, Inc. ("STI"), a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic immunotherapeutics based on Seneca Valley Virus (SVV-001), reported the poster presentation of Seneca Therapeutics’ abstract titled "Oncolytic Seneca Valley Virus (SVV) overcomes resistance to checkpoint inhibitor therapies in neuroendocrine and melanoma murine models expressing the receptor for SVV" (Press release, Seneca Therapeutics, APR 12, 2021, View Source [SID1234577925]). Key points from the presentation:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SVV-001 demonstrates the ability to turn cold tumors hot;
Intratumoral administration of SVV-001 in combination with a checkpoint inhibitor demonstrates up to six fold increase in anti-tumor response over SVV-001 alone or check point inhibitor therapy alone;
SVV-001 specifically targets, infects and kills TEM8 positive cancer cells. No cell killing was observed in normal cells;
RNA seq data confirm up regulation of genes known to stimulate an immune response;
A randomized Phase III clinical study comparing SVV-001 administered IT in combination with Opdivo and Yervoy compared to Opdivo and Yervoy alone in TEM8 positive neuroendocrine tumors and neuroendocrine carcinomas is planned to begin later in 2021. STI is also developing SVV-001 for intravenous use in TEM8 positive tumors as well as developing SVV-001 to deliver armed viruses to TEM8 positive tumor cells.

On April 12, 2021 Jubilant Therapeutics Inc. , a biopharmaceutical company developing oral, small molecule modulators to meet unmet medical needs in oncology and autoimmune diseases, reported preclinical data from two programs investigating the company’s PRMT5 inhibitor and PD-L1 inhibitor as anticancer agents will be unveiled today in a poster session at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2021, which will be held virtually from Nov. takes place until April 15 , 2021 (Press release, Jubilant Therapeutics, APR 12, 2021, View Source;pgid=1475&pressid=449 [SID1234577941]) .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to announce these important data from our PRMT5 and PD-L1 programs that demonstrate efficacy and tolerability in preclinical models," said Syed Kazmi, President and Chief Executive Officer of Jubilant Therapeutics Inc. "Our oral PRMT5 inhibitor has good plasma and sustained brain exposure resulting in potent target inhibition, tumor growth delay, and a survival benefit in both xenografts and orthotopic brain models . Our shorter half-life oral anti-PDL1 immunotherapeutics are an attractive alternative to current intravenous antibody therapies, especially in the maintenance phase, with the potential to limit immune-mediated toxicities and side effects through innovative dosage approaches while maintaining class-based broad anti-tumor efficacy. We look forward to continuing our work on these programs as we see great potential for treating various types of cancer. "

A link to the e-posters listed below is available on the AACR (Free AACR Whitepaper) website.

Title: Novel Small Molecular Weight PRMT5 Inhibitors for the Treatment of Cancer
Poster Number: 1128
Date and Time: April 10 , 2021 at 8:30 a.m. Eastern Daylight Time (EDT)
Session Title: Epigenetic Targets
Speaker: Dhanalakshmi Sivanandhan, et al.

Title: Novel Small Molecular Weight Inhibitors of PD-L1 / PD-1 Interaction
Poster Number: 1630
Date and Time: April 10 , 2021 at 8:30 a.m. Eastern Daylight Time (EDT)
Session Title: Immune Checkpoints
Speaker (r ): Dhanalakshmi Sivanandhan, et al.

The overexpression of PRMT5, which has been demonstrated in various types of cancer such as lymphatic cancer, lung cancer, breast cancer, glioblastoma, gastric cancer, etc., is considered to be an important factor in tumorigenicity due to its repressive function on the expression of tumor suppressor genes. The most important highlights from an evaluation that examined the inhibition of tumor growth by the PRMT5 inhibitor JBI-778 in various cancer cell lines as well as in glioblastoma are as follows:

JBI-778 is a potent PRMT5 inhibitor that acts selectively against other PRMTs;
JBI-778 is a potent PRMT5 inhibitor that acts selectively against other PRMTs;
This orally administered small molecule demonstrated anti-tumor activity in a mantle cell lymphoma model with an ED50 of <10 mg / kg and complete inhibition of tumor growth (97%) at a dose of 50 mg / kg; and
JBI-778 demonstrated sustained exposure of the brain and significant inhibition of tumor growth in an orthotopic glioblastoma model, resulting in a significant survival benefit.
JBI-778 is currently being investigated for the treatment of a variety of cancers and IND-approved studies have begun.

PD-L1 expression is an immune evasion mechanism that is exploited by many cancers, including melanoma, non-small cell lung cancer, and breast cancer, that enables cancer to progress and metastasize. Key findings from the PD-L1 / PD-1 Study, which examined the ability of JBI-1527 to inhibit PD-L1 and restore T cell proliferation and function, included:

JBI- 1527 is a potent, selective inhibitor of PD-L1, which induces the dimerization of the protein and thereby reduces the PD-L1-induced suppression of T-cell activation;
The inhibitor shows a similar modulation of cytokines as pembrolizumab in the BioMAP assay and competes with the anti-PD-L1 blocking antibody, suggesting a similar binding site on PD-L1; and
In syngeneic CT-26 and MC38-hPD-L1 models, the small molecule showed a strong inhibition of tumor growth, comparable to anti-PD-L1 mAb / atezolizumab, and was well tolerated.
Studies to further evaluate JBI-1527 and other substances are ongoing.

On April 12, 2021 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, reported that it has completed the sale of an additional 882,352 shares at the public offering price of US$4.24 per share pursuant to the underwriter’s over-allotment option granted in connection with the Company’s recent public offering, resulting in additional gross proceeds of approximately US$3.7 million (Press release, BriaCell Therapeutics, APR 12, 2021, View Source [SID1234578326]). After giving effect to the full exercise of the over-allotment option, the total gross proceeds for the public offering increased to approximately US$28.7 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ThinkEquity, a division of Fordham Financial Management, Inc., acted as sole book-running manager for the offering.

The Company intends to use the net proceeds to fund clinical trials and research and development and for general working capital and general corporate purposes.

A registration statement on Form F-1 (File No. 333-234292) relating to the offering was filed with the Securities and Exchange Commission ("SEC") and declared effective on February 23, 2021. The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673, or by email at [email protected]. Investors may also obtain these documents at no cost by visiting the SEC’s website at View Source

No securities regulatory authority has either approved or disapproved the contents of this news release. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.